CEO Jeff Roix spoke to BioCentury about how NeoPhore Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of neoantigens to turn “dark” tumors “light” that can be treated with immunotherapies.
06.08.2019
BioCentury's Emerging Company Profile
More news
13.11.2026
NeoPhore strengthens leadership as it prepares to take first-in-class DNA mismatch repair inhibitor into the clinic
Marianne Bjordal appointed CEO; Judit Molnar promoted to Chief Development Officer London, UK, 13 November 2026 – NeoPhore Limited, a company …
21.04.2026
AACR 2026 and AACR Cancer Discovery Article
NeoPhore Press Release: AACR 2026 and AACR Cancer Discovery Article London UK, 21 April 2026 NeoPhore, an immuno-oncology company, announces the …
16.09.2025
NeoPhore's CEO Presents at Morgan Stanley 23rd Annual Global Healthcare Conference | September 2025
NeoPhore's CEO - Michael Shih - recently presented the NeoPhore story at the Morgan Stanley Global Healthcare Conference on Monday September 8th …